FindTrial
Sign In

Exploring HER2 Overexpression and its Significance as a Biomarker in pathologic T-stage of de novo Muscle-Invasive Bladder Cancer

Exploring HER2 Overexpression and its Significance as a Biomarker in pathologic T-stage of de novo Muscle-Invasive Bladder Cancer: A prospective study in Retrospective multicenter Cohort

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008808
Enrollment
174
Registered
2023-09-21
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

GangNeung Asan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients were recently diagnosed with urothelial cancer and had no history of urothelial cancer. Patients who underwent transurethral resection of bladder tumor at Gangneung Asan Hospital between January 2005 and December 2013.

Exclusion criteria

Exclusion criteria: If have a upper urinary tract cancer is diagnosed diagnosed metastasized carcinoma If the carcinoma is not a cancer originating in the urinary tract epithelium

Design outcomes

Primary

MeasureTime frame
pathological T stage—

Secondary

MeasureTime frame
Prognosis (Pathologic T-stage, Survival)—

Countries

Korea, Republic of

Contacts

Public ContactSung Jin Kim

GangNeung Asan Hospital

bop1004@hanmail.net+82-33-610-3259

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026